Scoring systems for the post-thrombotic syndrome

Soosainathan, Arany; Moore, Hayley; Gohel, Manjit; Davies, Alun H.

doi:10.1016/j.jvs.2012.09.011

Cited by 141 publications

(82 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…30,51 In an effort to standardize the definition of PTS for research purposes, the International Society on Thrombosis and Haemostasis Subcommittee on Control of Anticoagulation recommended the Villalta scale as the most appropriate measure to diagnose and rate the severity of PTS, 13 as has a recent systematic review. 52 Kahn et al 13 provide a more detailed description of the Villalta scale and recommendations on how to administer it.…”

Section: Villalta Scalementioning

confidence: 99%

See 1 more Smart Citation

The Postthrombotic Syndrome: Evidence-Based Prevention, Diagnosis, and Treatment Strategies

Kahn¹,

Comerota²,

Cushman³

et al. 2014

Circulation

500

410

View full text Add to dashboard Cite

Section: Villalta Scalementioning

confidence: 99%

“…53 Although the measure does not rate the severity of PTS, it correlates well with QoL scores and identifies more severe PTS than the Villalta scale. 52,54 Potential shortcomings include a lack of sensitivity for milder forms of PTS and the fact that it is not quantitative.…”

Section: Ginsberg Measurementioning

confidence: 99%

The Postthrombotic Syndrome: Evidence-Based Prevention, Diagnosis, and Treatment Strategies

Kahn¹,

Comerota²,

Cushman³

et al. 2014

Circulation

500

410

View full text Add to dashboard Cite

“…Even more interestingly, some epidemiological trials have consistently demonstrated that CRP is positively associated with VTE risk, whereas the evidence that therapy with statins is eff ective at substantially decreasing the CRP concentration as part of their pleiotropic eff ects provides an- [26] demonstrated reduced levels of IL-6, IL-8 and P-selectin following three days of atorvastatin administration in VTE patients, without a decrease in CRP. Statins were also associated with reductions in MCP-1 and PAI-1 [27].…”

Section: Discussionmentioning

confidence: 94%

“…A score of 5 -9 signifi es mild disease, 10-14 moderate disease, and > 15 severe disease. Patients were assessed after three months by the same person using the Villalta scale and a score of 5 or more indicated the presence of PTS [12,13].…”

Section: Villaltamentioning

confidence: 99%

Effects of rosuvastatin as an adjuvant treatment for deep vein thrombosis

Norberto

Gastambide

Taylor

et al. 2016

Vasa

View full text Add to dashboard Cite

Summary:Background: Statins have been reported to help prevent the development and the recurrence of deep vein thrombosis (DVT). We conducted a prospective randomized clinical trial to compare the effects of rosuvastatin plus a low-molecular-weight heparin (LMWH), bemiparin, with conventional LMWH therapy in the treatment of DVT. Patients and methods: In total, 234 patients were randomized into two groups, 116 in the LMWH group and 118 in the statin plus LMWH group. All patients underwent lower limb duplex ultrasound and analytic markers at diagnosis and three months of follow-up. The fi nal analysis included 230 patients. Results: No signifi cant differences were observed in D-dimer levels after three months of follow-up between patients treated with LMWH+rosuvastatin compared to the LMWH group (802.51 + 1062.20 vs. 996.25 + 1843.37, p = 0.897). The group of patients treated with statins displayed lower levels of CRP (4.17 + 4.27 vs. 22.39 + 97.48, p = 0.018) after three months of follow-up. The Villalta scale demonstrated signifi cant differences between groups (3.45 + 6.03 vs. 7.79 + 5.58, p = 0.035). There was a signifi cant decrease in PTS incidence (Villalta score> 5) in the rosuvastatin group (38.3 % vs. 48.5%, p = 0.019). There were no differences in EuroQol score between groups. Conclusions: Adjuvant rosuvastatin treatment in patients diagnosed of DVT improve CRP levels and diminish PTS incidence.

show abstract

“…Use of recognized pediatric‐specific VTE and bleeding‐event classification criteria13 and of a pediatric PTS scoring system10, 37, 38 will also aid such comparisons.…”

Section: Discussionmentioning

confidence: 99%

Phase 3, single‐arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design

Luciani

Albisetti

Biss

et al. 2018

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

BackgroundAnticoagulant therapy for venous thromboembolism (VTE) in children is largely based on treatment recommendations for adults. However, differences in both physiology (ie, renal maturation and drug excretion) and developmental hemostasis must be considered when treating children, as such differences could affect dose appropriateness, safety and efficacy.ObjectivesTo address these concerns, a study was designed to evaluate the safety of dabigatran etexilate in children requiring secondary thrombus prevention in whom an initial VTE was associated with an identified risk factor that persisted after the acute VTE treatment period. We report herein the rationale and design of the study.Patients/MethodsThis phase 3, open‐label, single‐arm, multicenter, multinational, prospective cohort study will be conducted in ≥100 children aged 0 to <18 years at ~100 specialist sites worldwide. Children will be treated with dabigatran etexilate for 12 months, or for a shorter duration if their identified VTE risk factor resolves, as per current American College of Chest Physicians recommendations. A nomogram will be used to determine starting doses for each patient.ResultsThe primary outcomes of the study will be VTE recurrence, bleeding events, overall mortality, and VTE‐related mortality. Secondary outcomes will include occurrence of post‐thrombotic syndrome, the pharmacokinetics of dabigatran, and the need for dose adjustments during treatment. Data on adverse events during the study will also be collected.ConclusionThis study will evaluate the safety of dabigatran etexilate for the secondary prevention of VTE in children, in addition to providing further data to guide pediatric dosing with dabigatran.

show abstract

Scoring systems for the post-thrombotic syndrome

Abstract: The Villalta score, combined with a venous disease-specific quality-of-life questionnaire, should be considered the "gold standard" for the diagnosis and classification of post-thrombotic syndrome.

Cited by 141 publications

References 41 publications

The Postthrombotic Syndrome: Evidence-Based Prevention, Diagnosis, and Treatment Strategies

The Postthrombotic Syndrome: Evidence-Based Prevention, Diagnosis, and Treatment Strategies

Effects of rosuvastatin as an adjuvant treatment for deep vein thrombosis

Phase 3, single‐arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design

Contact Info

Product

Resources

About